You forgot to mention the new kid on the block in Starpharma’s arsenal. DepGem was ‘hidden’ in the Macquarie slide presentation. The drug Gemcitabine was originally developed and marketed by Eli Lilly as Gemzar and was approved for pancreatic cancers, non-small cell lung cancer and metastatic breast cancer.
From the slide show:
’Based on compelling DEP® preclinical data & investigator interest, combination DEP® docetaxel with gemcitabine (Gemzar®) trial targeting pancreatic cancer is in final stages of start-up.’
You forgot to mention the new kid on the block in Starpharma’s...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |